ERBB2 and breast carcinoma: Interestingly, we found a significantly positive correlation between MIR200CHG expression and the IC50 value of irinotecan (a chemotherapy drug for colon and lung cancers) and lapatinib (a targeted therapy for HER2-positive breast cancer) (Supplementary Fig. 4a, b), suggesting the potential value of MIR200CHG expression to predict the sensitivities of the two drugs.